End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
120,500.00 KRW | +0.50% | -16.84% | +75.15% |
08-22 | South Korean Shares Rise After BOK Rate Hold; Yuhan Gains on FDA Approval | MT |
08-22 | Yuhan Shares Jump 4% After US FDA Approves Anti-Cancer Drug for US Markets | MT |
Fiscal Period: December | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|---|---|---|
Revenues | 1,480B | 1,620B | 1,688B | 1,776B | 1,859B | |||||
Other Revenues, Total | - | -10 | 10 | - | -10 | |||||
Total Revenues | 1,480B | 1,620B | 1,688B | 1,776B | 1,859B | |||||
Cost of Goods Sold, Total | 1,050B | 1,062B | 1,164B | 1,259B | 1,294B | |||||
Gross Profit | 430B | 557B | 523B | 517B | 565B | |||||
Selling General & Admin Expenses, Total | 298B | 308B | 348B | 354B | 369B | |||||
Provision for Bad Debts | 351M | 1.19B | -1.42B | 2.08B | 1.42B | |||||
R&D Expenses | 96.9B | 143B | 107B | 107B | 120B | |||||
Depreciation & Amortization - (IS) | 10.08B | 11.39B | 11.14B | 7.85B | 6.83B | |||||
Amortization of Goodwill and Intangible Assets - (IS) | 2.54B | 2.47B | 2.41B | 1.46B | 2.37B | |||||
Other Operating Expenses | 9.57B | 7.17B | 7.61B | 8.2B | 8.69B | |||||
Other Operating Expenses, Total | 417B | 473B | 475B | 481B | 508B | |||||
Operating Income | 12.54B | 84.26B | 48.6B | 36.03B | 56.67B | |||||
Interest Expense, Total | -3.1B | -2.71B | -2.94B | -3.47B | -6.3B | |||||
Interest And Investment Income | 17.24B | 6.9B | 5.24B | 10.27B | 13.85B | |||||
Net Interest Expenses | 14.14B | 4.19B | 2.3B | 6.81B | 7.55B | |||||
Income (Loss) On Equity Invest. | 37.6B | 61.12B | 75.86B | 42.38B | 81.37B | |||||
Currency Exchange Gains (Loss) | -3.49B | -18.64B | 19.65B | 19.17B | 2.31B | |||||
Other Non Operating Income (Expenses) | -1.84B | -21.01B | -7.93B | -6.63B | -12.18B | |||||
EBT, Excl. Unusual Items | 58.94B | 110B | 138B | 97.75B | 136B | |||||
Gain (Loss) On Sale Of Investments | 899M | 2.7B | 1.79B | 4.11B | 3.28B | |||||
Gain (Loss) On Sale Of Assets | -2.53M | 132B | -624M | 180M | 132M | |||||
Asset Writedown | -4.92B | -4.92B | -13.58B | -7.11B | -4.6B | |||||
EBT, Incl. Unusual Items | 54.92B | 240B | 126B | 94.93B | 135B | |||||
Income Tax Expense | 18.31B | 49.49B | 26.93B | 4.33B | 508M | |||||
Earnings From Continuing Operations | 36.61B | 190B | 99.13B | 90.59B | 134B | |||||
Net Income to Company | 36.61B | 190B | 99.13B | 90.59B | 134B | |||||
Minority Interest | 3.39B | 2.36B | 3.46B | 4.55B | 2.06B | |||||
Net Income - (IS) | 40.01B | 193B | 103B | 95.14B | 136B | |||||
Preferred Dividend and Other Adjustments | 784M | 3.56B | 1.73B | 1.54B | 2.1B | |||||
Net Income to Common Incl Extra Items | 39.22B | 189B | 101B | 93.61B | 134B | |||||
Net Income to Common Excl. Extra Items | 39.22B | 189B | 101B | 93.61B | 134B | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 517.15 | 2.5K | 1.33K | 1.19K | 1.7K | |||||
Basic EPS - Continuing Operations | 517.15 | 2.5K | 1.33K | 1.19K | 1.7K | |||||
Basic Weighted Average Shares Outstanding | 75.84M | 75.74M | 75.59M | 78.94M | 78.71M | |||||
Net EPS - Diluted | 517.15 | 2.5K | 1.33K | 1.19K | 1.7K | |||||
Diluted EPS - Continuing Operations | 517.15 | 2.5K | 1.33K | 1.19K | 1.7K | |||||
Diluted Weighted Average Shares Outstanding | 75.84M | 75.74M | 75.59M | 78.94M | 78.71M | |||||
Normalized Basic EPS | 530.5 | 938.18 | 1.19K | 831.55 | 1.1K | |||||
Normalized Diluted EPS | 530.5 | 938.18 | 1.19K | 831.55 | 1.1K | |||||
Dividend Per Share | 329.08 | 329.08 | 362.81 | 362.81 | 428.57 | |||||
Payout Ratio | 57.27 | 12.34 | 24.31 | 27.41 | 20.04 | |||||
Supplemental Items | ||||||||||
EBITDA | 71.19B | 144B | 101B | 79.05B | 101B | |||||
EBITA | 17.1B | 89.04B | 54.1B | 40.5B | 62.88B | |||||
EBIT | 12.54B | 84.26B | 48.6B | 36.03B | 56.67B | |||||
Effective Tax Rate - (Ratio) | 33.33 | 20.63 | 21.37 | 4.57 | 0.38 | |||||
Normalized Net Income | 40.23B | 71.06B | 90B | 65.65B | 86.88B | |||||
Supplemental Operating Expense Items | ||||||||||
Advertising Expense | 85.48B | 78.97B | 108B | 113B | 110B | |||||
Selling and Marketing Expenses | 134B | 130B | 163B | 173B | 176B | |||||
General and Administrative Expenses | 2.51B | 2.04B | 2.17B | 2.93B | 3.31B | |||||
Research And Development Expense From Footnotes | 96.9B | 143B | 107B | 107B | 120B | |||||
Maintenance & Repair Expenses, Total | 978M | 1.04B | 1.24B | 989M | 1.35B | |||||
Stock-Based Comp., SG&A Exp. (Total) | - | 591M | 689M | 345M | 145M | |||||
Total Stock-Based Compensation | - | 591M | 689M | 345M | 145M |